STEP Young reports initial semaglutide results in children under 12
A company release reports headline phase 3 results in 165 children. Full peer-reviewed results are not yet available.
Read story →Documented updates
Obesity and GLP-1 treatment news
Regulatory changes, safety and research explained with primary sources and visible limitations.
FDA expands Mounjaro's cardiovascular indication in the United States
The decision concerns adults with type 2 diabetes at high cardiovascular risk; it is not a general obesity authorisation.
Read story →European Wegovy documentation now includes an oral formulation for adults
EMA published the assessment supporting tablets as an alternative to injection for adults within the authorised indication.
Read story →EMA publishes its assessment of the liraglutide medicine Ablymico
The EU authorisation concerns liraglutide for weight management and does not mean the product is already available in every country.
Read story →Barcelona study examines body composition and strength during semaglutide treatment
The observational study adds routine-care data, but its retrospective single-centre design limits causal conclusions.
Read story →Phase 3 trial publishes survodutide results in adults with obesity
SYNCHRONIZE-1 studied an investigational medicine; published trial findings are not regulatory approval.
Read story →STEP 12 reports semaglutide results in Chinese adults
The phase 3b trial broadens evidence in a Chinese population while leaving population and health-system differences relevant.
Read story →Multicentre analysis studies tirzepatide use among young people in routine care
The US observational study describes routine use in young people with type 2 diabetes and/or obesity; it is not a randomised trial.
Read story →Oral aleniglipron reports phase 2b obesity results
ACCESS tested an oral small-molecule GLP-1 agonist in 230 adults; it remains an investigational candidate.
Read story →Spanish prospective study evaluates tirzepatide in routine care
The Spanish study adds observational effectiveness and safety data, with the limitations of real-world care.
Read story →WHO calls for safer, supervised use of GLP-1 medicines
Safety committees highlight informal purchasing, off-label use and misinformation without issuing a warning against the entire class.
Read story →UK MHRA warns against accelerated dosing and illegal GLP-1 sales
The UK notice says increasing doses or buying through informal channels can cause harm.
Read story →